Onco IX (PHC-102)

Onco IX (PHC-102)

Onco IX (PHC-102) is a 99mTc labelled small molecule radiotracer for the non-invasive detection of carbonic anhydrase IX (CAIX) expressing solid tumors. The product consists of (i) a CAIX ligand derived from acetazolamide, (ii) a non-cleavable spacer and (iii) a peptide 99mTC chelator.

CAIX is a validated target, which is expressed in the majority of Renal Cell Carcinoma (RCC) patients, but also in a proportion of patients with other malignancies (e.g., ~30% of patients with Colorectal Carcinoma).

In preclinical studies, PHC-102 demonstrated high tumor uptake and excellent tumor-to-kidney ratios (i.e., 3:1 already 6 hours after intravenous administration).

The favorable tumor uptake and biodistribution of Onco IX has been validated by the successful imaging of primary and secondary RCC tumors in human patients.
 
ONGOING CLINICAL TRIALS

  • A phase I study for the clinical development of Onco IX (PHC-102) as imaging agent in patients with RCC.

SELECTED REFERENCES

Kulterer et al. (2020) J Nucl Med, Online ahead of print
Cazzamalli et al. (2018) Clin Cancer Res, 24, 3656-67
Cazzamalli et al. (2018) J Am Chem Soc, 140, 1617-21
Cazzamalli et al. (2017) J Control Release, 246, 39-45
Cazzamalli et al., (2016) Mol Cancer Ther, 15, 2926-35
Krall et al. (2016) J. Nucl Med, 57, 943-9
Wichert et al. (2015) Nat Chem, 7, 241-9
Krall et al. (2014) Chem Sci, 5, 3640-4
Krall et al. (2014) Angew Chem Int Ed, 53, 4231-35

This website or its third party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. If you want to know more or withdraw your consent to all of the cookies, please refer to the cookie policy. By closing this banner, scrolling this page, clicking a link or continuing to browse otherwise, you agree to the use of cookies.

I Accept Cookie Policy
X